

Type	Group No.	Session Name	Presentation No.	Submission No.	Title	First Name	Family Name	Country/District	Day	Session Start	Start of each	End of each	Min.	Place
Poster	Poster Group 1	Biliary Poster Session 1	BP1-1	10182	Divergent Chromosomal Architectures in Cholangiocarcinoma Cell Lines with Comparable Proliferation Rates: Implications for Genomic Heterogeneity	Ratana	Leksomboon	Thailand	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 1	Biliary Poster Session 1	BP1-2	10148	The Impact and Mechanisms of YES1 in Intrahepatic Cholangiocarcinoma Progression	Tao	Han	China	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 1	Biliary Poster Session 1	BP1-3	10019	Clinicopathological Features of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Intrahepatic Cholangiocarcinoma	Zhaohui	Tang	China	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 1	Biliary Poster Session 1	BP1-4	10056	Prognostic Impact of Etiologies on Intrahepatic Cholangiocarcinoma: An Analysis of a Nationwide Registry	Kazuya	Okushin	Japan	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 1	Biliary Poster Session 1	BP1-5	10161	Dose-response Association between Waist Circumference and Risk of Cholangiocarcinoma: A Nationwide Population-based Cohort Study	Joo-Hyun	Park	Korea	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 2	Biliary Poster Session 2	BP2-1	10141	Clinical Utility of Peroral Cholangioscopy-Guided Biopsy in the Diagnosis of Biliary Lesions	Nobuhiro	katsukura	Japan	April 2 (Day 1)	18:30	18:30	18:36	6	Poster Area
Poster	Poster Group 2	Biliary Poster Session 2	BP2-2	10063	Optimal Biliary Drainage for Malignant Hilar Biliary Obstruction	Naminatsu	Takahara	Japan	April 2 (Day 1)	18:30	18:36	18:42	6	Poster Area
Poster	Poster Group 2	Biliary Poster Session 2	BP2-3	10089	Selective Endoscopic Nasobiliary Drainage to Determine the Resection Range for Intraductal Papillary Neoplasm of the Bile Duct with an Indeterminate Primary Site: A Case Report	Junichi	Kaneko	Japan	April 2 (Day 1)	18:30	18:42	18:48	6	Poster Area
Poster	Poster Group 2	Biliary Poster Session 2	BP2-4	10133	Case Report of Primary Hepatic Carcinoma Complicated with Cholangiolar Sarcomatoid Carcinoma	Jiawei	Zhang	China	April 2 (Day 1)	18:30	18:48	18:54	6	Poster Area
Poster	Poster Group 3	Biliary Poster Session 3	BP3-1	10173	Advances in the Management of Intrahepatic Cholangiocarcinoma and Temporal Changes in Prognosis: A Prospective Long-Term Real-World Data Analysis	Sumio	Hirose	Japan	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 3	Biliary Poster Session 3	BP3-2	10127	Hepatic Arterial Infusion Chemotherapy with New FP (NFP) for Unresectable Intrahepatic Cholangiocarcinoma: A Single-Center Retrospective Study	Hiroto	Ota	Japan	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 3	Biliary Poster Session 3	BP3-3	10067	Analysis of Prognostic Factors for ICI Combination Regimens in Unresectable Biliary Tract Cancer	Mai	Kitahara	Japan	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 3	Biliary Poster Session 3	BP3-4	10187	Immune Checkpoint Inhibitors Combined with Chemotherapy and Comprehensive Genomic Profiling Test for Advanced Biliary Tract Cancer in Our Hospital	Morito	Ikeda	Japan	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 3	Biliary Poster Session 3	BP3-5	10209	The Impact of Antibiotics on ICI Combination Chemotherapy in Advanced Biliary Tract Cancer	Shota	Iwahara	Japan	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 3	Biliary Poster Session 3	BP3-6	10045	Two Cases of Unresectable Combined Hepatocellular-Cholangiocarcinoma Treated with Immune Checkpoint Inhibitors	Yasuhide	Motoyoshi	Japan	April 2 (Day 1)	18:00	18:30	18:36	6	Poster Area
Poster	Poster Group 4	Basic & Experimental Poster Session 1	BEP1-1	10026	SLC12A2-driven Suppression of Hepatic Lipolysis Shapes a Tumor-promoting Microenvironment in Metabolically Steatotic Livers	Yotaro	Kudo	Japan	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 4	Basic & Experimental Poster Session 1	BEP1-2	10196	Accumulation of Autophagy-specific Substrate p62/SQSTM1 is Associated with Multinucleation in Human Hepatocellular Carcinoma	Shunhei	Yamashita	Japan	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 4	Basic & Experimental Poster Session 1	BEP1-3	10117	Investigation of the Anti-tumor and Anti-HBV Effects of the Host Factor FAH	Shouchi	Namikawa	Japan	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 4	Basic & Experimental Poster Session 1	BEP1-4	10134	Ameliorative Role of Phytosterol Pre-Treatment in N-Nitrosodiethylamine Induced Oxidative Stress in Female Albino Rats	Rahul	Kumar	India	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 5	Basic & Experimental Poster Session 2	BEP2-1	10022	Withdrawn									
Poster	Poster Group 5	Basic & Experimental Poster Session 2	BEP2-2	10109	Multi-omics Profiling Reveals the Prognostic Features and Tumor Microenvironment of High-stemness HCC	Yu	Luo	China	April 2 (Day 1)	18:30	18:30	18:36	6	Poster Area
Poster	Poster Group 5	Basic & Experimental Poster Session 2	BEP2-3	10145	ZIP1-CAF Shapes the Immunosuppressive Microenvironment to Drive Hepatocellular Carcinoma Progression	Jiangxi	Liu	China	April 2 (Day 1)	18:30	18:36	18:42	6	Poster Area
Poster	Poster Group 5	Basic & Experimental Poster Session 2	BEP2-4	10132	Microenvironmental Analysis of Resistance to Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma: Involvement of High M2BP Expression and Inflammatory Cancer-Associated Fibroblasts	Katsuya	Nagaoka	Japan	April 2 (Day 1)	18:30	18:42	18:48	6	Poster Area
Poster	Poster Group 5	Basic & Experimental Poster Session 2	BEP2-5	10176	Association of HAMP Expression and CD8+ T-cell Infiltration with Atezolizumab plus Bevacizumab Response in Hepatocellular Carcinoma	Shun	Nakamura	Japan	April 2 (Day 1)	18:30	18:48	18:54	6	Poster Area
Poster	Poster Group 6	Basic & Experimental Poster Session 3	BEP3-1	10192	Mutation Profiles of TERT, TP53, and CTNNA1 Genes from Circulating Cell Free DNA as Non-Invasive Prognostic Biomarkers in HBV-Induced Hepatocellular Carcinoma	Afzalun	Nessa	Bangladesh	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 6	Basic & Experimental Poster Session 3	BEP3-2	10201	Performance of Circulating 5-Hydroxymethylcytosine Epigenetic Signatures in Detecting Hepatocellular Carcinoma Among Patients With Cirrhosis	Rishabh	Sharma	India	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 6	Basic & Experimental Poster Session 3	BEP3-3	10010	Identification of Novel Prognostic Biomarkers and Molecular Pathogenesis Insights in Hepatocellular Carcinoma through Integrated Multi-Database Analysis	Md Shariful	Islam	USA	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 6	Basic & Experimental Poster Session 3	BEP3-4	10222	The VETC Associated Trabecular Subtypes in Non-cirrhotic HCC is Defined by Loss of Tumor Suppressor and Downregulation of Ribosomal Genes	Archana	Rastogi	India	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 6	Basic & Experimental Poster Session 3	BEP3-5	10197	Hepatocellular Carcinoma in Armenia: Primary Assessment of Molecular Alterations	Hasmik	Ghazinyan	Armenia	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 7	Basic & Experimental Poster Session 4	BEP4-1	10154	Global Research Landscape and Thematic Evolution of Immune Cell Metabolic Reprogramming in Liver Disease and Hepatic Oncology: A Bibliometric and Science Mapping Analysis	Ziteng	Wang	China	April 2 (Day 1)	18:30	18:30	18:36	6	Poster Area
Poster	Poster Group 7	Basic & Experimental Poster Session 4	BEP4-2	10066	The Relationship between the Expression of Tumor Microenvironment-related Genes and the Gene Mutations of Hepatocellular Carcinoma from TCGA Data	Yoshinari	Asaoka	Japan	April 2 (Day 1)	18:30	18:36	18:42	6	Poster Area
Poster	Poster Group 7	Basic & Experimental Poster Session 4	BEP4-3	10021	Integrative Machine Learning and Experimental Validation Identify MYBL2 as a Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma	Ya-Ling	Yang	Taiwan	April 2 (Day 1)	18:30	18:42	18:48	6	Poster Area
Poster	Poster Group 7	Basic & Experimental Poster Session 4	BEP4-4	10203	Clinical Significance of Serum VEGF Levels in Patients with Unresectable Hepatocellular Carcinoma Treated with Durvalumab plus Tremelimumab	Yutaka	Yasui	Japan	April 2 (Day 1)	18:30	18:48	18:54	6	Poster Area
Poster	Poster Group 7	Basic & Experimental Poster Session 4	BEP4-5	10225	Impact of Hepatocyte Nuclear Factor-1 Alpha Genetic Variants on Hepatocellular Carcinoma Susceptibility among Patients with and without Diabetes Mellitus	Mohamed	Abdel-Samiee	Egypt	April 2 (Day 1)	18:30	18:54	19:00	6	Poster Area
Poster	Poster Group 8	Hepatitis & Chronic Liver Disease Poster Session 1	HCP1-1	10042	Risk Factors for Hepatocellular Carcinoma Development after Direct-acting Antiviral Therapy in Hepatitis C: A Long-term Follow-up Study	Rino	Nakamura	Japan	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 8	Hepatitis & Chronic Liver Disease Poster Session 1	HCP1-2	10138	HCC Development in HCV-Infected Patients after Virological Response	Narina	Sargsyants	Armenia	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 8	Hepatitis & Chronic Liver Disease Poster Session 1	HCP1-3	10027	Early Detection of De Novo Hepatocellular Carcinoma by AFP-L3 Fraction Following SVR for HCV: A Case Report	Takahisa	Sato	Japan	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 8	Hepatitis & Chronic Liver Disease Poster Session 1	HCP1-4	10081	A Case of Hepatocellular Carcinoma with Decompensated Hepatitis C-related Liver Cirrhosis that Achieved a Sustained Virological Response after Retreatment with Glecaprevir/Pibrentasvir	Satoru	Kakizaki	Japan	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 8	Hepatitis & Chronic Liver Disease Poster Session 1	HCP1-5	10115	Ruptured Hepatocellular Carcinoma in an Untreated HCV Patient: Emergency Management, Viral Eradication, and Aggressive Recurrence	Kentaro	Takahashi	Japan	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 9	Hepatitis & Chronic Liver Disease Poster Session 2	HCP2-1	10015	Hepatocellular Carcinoma in Japanese Autoimmune Hepatitis: Management and Outcomes	Tomoko	Tadokoro	Japan	April 2 (Day 1)	18:30	18:30	18:36	6	Poster Area
Poster	Poster Group 9	Hepatitis & Chronic Liver Disease Poster Session 2	HCP2-2	10049	A Study on Hepatocellular Carcinoma with Autoimmune Hepatitis as Background Liver Disease	Hideo	Yoshida	Japan	April 2 (Day 1)	18:30	18:36	18:42	6	Poster Area
Poster	Poster Group 9	Hepatitis & Chronic Liver Disease Poster Session 2	HCP2-3	10142	Late-Onset Hepatic Failure (LOHF) Caused by Seronegative Acute-Onset Autoimmune Hepatitis Requiring Liver Transplantation	Keigo	Misawa	Japan	April 2 (Day 1)	18:30	18:42	18:48	6	Poster Area
Poster	Poster Group 9	Hepatitis & Chronic Liver Disease Poster Session 2	HCP2-4	10057	Validation of PBC-10 in Japanese Patients with Primary Biliary Cholangitis	Akihito	Takeuchi	Japan	April 2 (Day 1)	18:30	18:48	18:54	6	Poster Area
Poster	Poster Group 9	Hepatitis & Chronic Liver Disease Poster Session 2	HCP2-5	10025	Changes in Symptomatic Presentation at Diagnosis and Prognostic Impact in Primary Biliary Cholangitis	Akihito	Takeuchi	Japan	April 2 (Day 1)	18:30	18:54	19:00	6	Poster Area
Poster	Poster Group 10	Hepatitis & Chronic Liver Disease Poster Session 3	HCP3-1	10124	Aetiology and Specific Risk of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease	Yu Xi	Tan	Singapore	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 10	Hepatitis & Chronic Liver Disease Poster Session 3	HCP3-2	10087	Characteristics of Hepatocellular Carcinoma Arising from Alcohol-associated Steatotic Liver Disease	Yuri	Ogasawara	Japan	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 10	Hepatitis & Chronic Liver Disease Poster Session 3	HCP3-3	10185	Intermittent Fasting, Liver Fibrosis, and Hepatocellular Carcinoma Risk in Non-Alcoholic Fatty Liver Disease: A Scoping Review	Inas	Karimi	Indonesia	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 10	Hepatitis & Chronic Liver Disease Poster Session 3	HCP3-4	10159	Sarcopenia in Cirrhotic Patients: Prevalence, Prognostic Impact, and Clinical Outcomes	Atteyat	Sameya	Saudi Arabia	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 10	Hepatitis & Chronic Liver Disease Poster Session 3	HCP3-5	10075	Acid-Suppressing Therapy and the Risk of Hepatic Encephalopathy in Cirrhosis: A Prospective Cohort Study	Keiichi	Katayama	Japan	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 11	Hepatitis & Chronic Liver Disease Poster Session 4	HCP4-1	10174	Global Trends in Liver Cancer Attributable to Hepatitis B: Insights from the Global Burden of Disease 2023 Study	Ekram	Hasanin	Libya	April 2 (Day 1)	18:30	18:30	18:36	6	Poster Area
Poster	Poster Group 11	Hepatitis & Chronic Liver Disease Poster Session 4	HCP4-2	10125	Global Prevalence and Incidence of Primary Sclerosing Cholangitis: An Updated Meta-Analysis	Asvin	Selvakumar	Singapore	April 2 (Day 1)	18:30	18:36	18:42	6	Poster Area
Poster	Poster Group 11	Hepatitis & Chronic Liver Disease Poster Session 4	HCP4-3	10126	Genome-wide Association Study of TG/HDL Ratio in 424,865 UK Biobank Participants	Jordan	Low	Singapore	April 2 (Day 1)	18:30	18:42	18:48	6	Poster Area
Poster	Poster Group 11	Hepatitis & Chronic Liver Disease Poster Session 4	HCP4-4	10208	Treatment Outcomes of Triple Therapy for 816 NAFLD Patients in Mongolia	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:30	18:48	18:54	6	Poster Area
Poster	Poster Group 12	Hepatitis & Chronic Liver Disease Poster Session 5	HCP5-1	10199	Hepatoprotective Drugs for the Prevention of Liver Injury among Patients at Risk for Drug-Induced Liver Injury or Chemotherapy-Induced Transaminitis: A Systematic Review and Meta-Analysis	Cheryl J.	Toledano	Philippines	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 12	Hepatitis & Chronic Liver Disease Poster Session 5	HCP5-2	10163	Five-year Active Surveillance of Unresectable Hepatic Epithelioid Hemangioendothelioma Diagnosed by Repeat Liver Biopsy	Noriyo	Yamashiki	Japan	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 12	Hepatitis & Chronic Liver Disease Poster Session 5	HCP5-3	10121	Efficacy of a Novel Ultra Slim Therapeutic Upper Gastrointestinal Endoscope for Pediatric Esophageal Varices A Case Report	Ryosuke	Kawanishi	Japan	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 13	Hepatitis & Chronic Liver Disease Poster Session 6	HCP6-1	10216	Steep Declining Trends of Hepatitis Virus Prevalence in Mongolia over the last 20 years, a Nationwide Study	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 13	Hepatitis & Chronic Liver Disease Poster Session 6	HCP6-2	10219	Routes of New Viral Hepatitis Infections in Modern Mongolia	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 13	Hepatitis & Chronic Liver Disease Poster Session 6	HCP6-3	10212	Alcohol Consumption and Its Association with HCC in Mongolia according to A-HOC Study	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 13	Hepatitis & Chronic Liver Disease Poster Session 6	HCP6-4	10220	Association of HbA1c with Liver Steatosis and Fibrosis in Mongolia	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 13	Hepatitis & Chronic Liver Disease Poster Session 6	HCP6-5	10058	Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights from a Decade of Follow-Up	Akihito	Takeuchi	Japan	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 14	HCC Poster Session 1	HP1-1	10191	A-HOC (APASL Hepatology/Oncology Consortium): A Foundational Dataset for Future Hepatology and Oncology Research	Hitoshi	Mochizuki	Japan	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 14	HCC Poster Session 1	HP1-2	10205	A-HOC Study on 1108 Patients Under Surveillance for Liver Cancer in Mongolia	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 14	HCC Poster Session 1	HP1-3	10218	Clinical and Epidemiological Analysis of Liver Cancer Patients Under Primary Health Care Center Surveillance in Mongolia	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 14	HCC Poster Session 1	HP1-4	10012	Clinical Characteristics and Survival Outcomes of Hepatocellular Carcinoma at Dr. Moewardi Regional Tertiary Referral Hospital, Indonesia: A Retrospective Study	Triyanta_Yuli	Pramana	Indonesia	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 14	HCC Poster Session 1	HP1-5	10179	Discrepancy between the Real Clinical Status of Patients with HCC and Expectations from HCC Surveillance: A Single Center Study	Jiwoong	Jang	Korea	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 15	HCC Poster Session 2	HP2-1	10217	Combined Assessment of Ferritin, AFP, and PIVKA-II in the Diagnosis of Hepatocellular Carcinoma	Amarsanaa	Jazag	Mongolia	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 15	HCC Poster Session 2	HP2-2	10054	Clinical Impact of the aMAP Risk Score and Hepatocellular Carcinoma on Outcomes after Rifaximin Therapy for Hepatic Encephalopathy	Satoshi	Takakusagi	Japan	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 15	HCC Poster Session 2	HP2-3	10214	Hepatic Encephalopathy among HCC Patients Monitored for 2 Years, A-HOC									

Type	Group No.	Session Name	Presentation No.	Submission No.	Title	First Name	Family Name	Country/District	Day	Session Start	Start of each	End of each	Min.	Place
Poster	Poster Group 15	HCC Poster Session 2	HP2-4	10018	Current Status of Hypozincemia and Zinc Supplementation in Patients with Hepatocellular Carcinoma at Our Hospital	Takeharu	Asano	Japan	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 15	HCC Poster Session 2	HP2-5	10200	A Case of Mucosa-associated Lymphoid Tissue Lymphoma of the Liver Recurred with the Subsequent Palatal Lesion	Ryutoku	Kondo	Japan	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 16	HCC Poster Session 3	HP3-1	10113	Long-Term Clinical Course of Hepatocellular Carcinoma	Keisuke	Hamamura	Japan	April 2 (Day 1)	18:00	18:00	18:06	6	Poster Area
Poster	Poster Group 16	HCC Poster Session 3	HP3-2	10190	Systemic Therapy for Advanced Hepatocellular Carcinoma in a Single Center	Toru	Arano	Japan	April 2 (Day 1)	18:00	18:06	18:12	6	Poster Area
Poster	Poster Group 16	HCC Poster Session 3	HP3-3	10226	Treatment Modalities and Response Patterns in Hepatocellular Carcinoma: Real-World Data from a Turkish Cohort	Murat	Kekilli	Turkey	April 2 (Day 1)	18:00	18:12	18:18	6	Poster Area
Poster	Poster Group 16	HCC Poster Session 3	HP3-4	10224	Clinical and Etiologic Characteristics of Hepatocellular Carcinoma in a Turkish Cohort	Gulden	Bilican	Turkey	April 2 (Day 1)	18:00	18:18	18:24	6	Poster Area
Poster	Poster Group 16	HCC Poster Session 3	HP3-5	10180	Ectopic Retroperitoneal Hepatocellular Carcinoma Mimicking GIST with Portal Vein Tumor Thrombosis	Prabhath	Dasanayaka	Sri Lanka	April 2 (Day 1)	18:00	18:24	18:30	6	Poster Area
Poster	Poster Group 17	Radiology Poster Session 1	RP1-1	10024	Diversity of Imaging Features in Intrahepatic Mass-forming Cholangiocarcinoma Across Different Background Liver Conditions	Kazuto	Kozaka	Japan	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 17	Radiology Poster Session 1	RP1-2	10030	Clinical Feasibility of Automated Image–Based Registration–Supported Ultrasound–CT Fusion and Its Patient-Dependent Limitations	Ryo	Yano	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 17	Radiology Poster Session 1	RP1-3	10055	ADC Increase as a Biomarker of Tumor Shrinkage and PIVKA-II Decline after SBRT in Hepatocellular Carcinoma: A Prospective Study	Osamu	Tanaka	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 17	Radiology Poster Session 1	RP1-4	10086	Predictors of Compensatory Hepatic Hypertrophy following Carbon Ion Radiotherapy in Hepatocellular Carcinoma and its Association with Long-term Clinical Outcomes	Takeshi	Hatanaka	Japan	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 18	Radiology Poster Session 2	RP2-1	10009	The Roll of Cyber-knife Treatment on Advanced Hepatocellular Carcinoma	Takamasa	Ohki	Japan	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 18	Radiology Poster Session 2	RP2-2	10052	Efficacy and Safety of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in BCLC Stage A	Kodai	Suzue	Japan	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 18	Radiology Poster Session 2	RP2-3	10059	Stereotactic Body Radiation Therapy for Intrahepatic Lesions of Hepatocellular Carcinoma	Yasuki	Niimura	Japan	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 18	Radiology Poster Session 2	RP2-4	10085	Case Study of Advanced Hepatocellular Carcinoma Treated with Combined Radiation Therapy and Chemotherapy	Hideo	Yoshida	Japan	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 18	Radiology Poster Session 2	RP2-5	10114	Treatment Outcomes of B-RTO and Subsequent Changes in Hepatic Functional Reserve	Ryosuke	Hayakawa	Japan	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area
Poster	Poster Group 19	Surgical Poster Session 1	SP1-1	10040	Evaluation of Stepwise Indocyanine Green Dosing for Hepatic Segment Visualization in a Mouse Model	Shuhei	Kanda	Japan	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 19	Surgical Poster Session 1	SP1-2	10082	Development of Ultra-Fine 3D Images of Intrahepatic Glissonean Structure	Kazuma	Hasegawa	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 19	Surgical Poster Session 1	SP1-3	10036	Routine Use of Intravenous Acetaminophen Safely Enhances Pain Control After Minimally Invasive Hepatectomies	Kei	Furuya	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 19	Surgical Poster Session 1	SP1-4	10048	A Predictive Nomogram for Postoperative Delirium after Hepatectomy for Hepatocellular Carcinoma: Development, Validation, and Clinical Utility Analysis	Shu	Inagaki	Japan	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 19	Surgical Poster Session 1	SP1-5	10034	Redox-Active Compound Accelerates Liver Regeneration and Attenuates Acute Injury in Mouse Models: Relevance to Liver Tumor Resection	Hyun Ae	Woo	Korea	April 3 (Day 2)	15:00	15:24	15:30	6	Poster Area
Poster	Poster Group 20	Surgical Poster Session 2	SP2-1	10072	Conversion Surgery for Hepatocellular Carcinoma following Multidisciplinary Treatment	Masayuki	Honda	Japan	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 20	Surgical Poster Session 2	SP2-2	10175	A Case of Conversion Surgery for a Huge Unresectable Hepatocellular Carcinoma with a Pathological Complete Response after Short-term Immune Checkpoint Inhibitor Therapy Ceased by Liver Dysfunction	Hiroe	Toyoda	Japan	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 20	Surgical Poster Session 2	SP2-3	10195	A Case of Advanced Hepatocellular Carcinoma Responded to Durvalumab Monotherapy, Leading to Conversion Surgery	Hiroto	Ota	Japan	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 20	Surgical Poster Session 2	SP2-4	10104	A Case of Retroperitoneal Metastasis of Hepatocellular Carcinoma Resected Laparoscopically	Tatsunori	Nadaya	Japan	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 20	Surgical Poster Session 2	SP2-5	10193	Multidisciplinary Management for Recurrence after Liver Resection for Hepatocellular Carcinoma	Osamu	Aramaki	Japan	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area
Poster	Poster Group 21	Surgical Poster Session 3	SP3-1	10080	Characteristics of HCV-Related Hepatocellular Carcinoma Patients Achieving Long-Term Cancer-Free Survival after Repeated Hepatectomy in SVR Status	Yuji	Iimuro	Japan	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 21	Surgical Poster Session 3	SP3-2	10149	Cure by Liver Transplantation of HCV-related Decompensated Cirrhosis with Hepatocellular Carcinoma developing 14 Years after IFN-induced SVR	Rintaro	Hamazaki	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 21	Surgical Poster Session 3	SP3-3	10206	ALPPS followed by Salvage LDLT for Recurrent HCC	Alp	Atasoy	Turkey	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 21	Surgical Poster Session 3	SP3-4	10215	Immunosuppressive Medication Non-adherence in Liver Transplantation Adult Recipients in Vietnam	Nguyen Thai Van	Anh	Viet Nam	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 21	Surgical Poster Session 3	SP3-5	10023	A Resected Case of Gallbladder Carcinoma Difficult to Differentiate from Metastatic Gastric Cancer to the Gallbladder	Kenji	Hirano	Japan	April 3 (Day 2)	15:00	15:24	15:30	6	Poster Area
Poster	Poster Group 22	Local Therapy Poster Session	LTP-1	10155	Percutaneous Radiofrequency Ablation in Early-stage Hepatocellular Carcinoma	Shinpei	Sato	Japan	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 22	Local Therapy Poster Session	LTP-2	10035	EUS-Guided Ethanol Injection for Hepatocellular Carcinoma Inaccessible by Percutaneous Approach: A Successful Case of Local Tumor Control	Takuro	Nishiwaki	Japan	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 22	Local Therapy Poster Session	LTP-3	10037	Efficacy and Safety of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in the Caudate Lobe: A Comparative Study with Radiofrequency Ablation Authors	Yuki	Tamura	Japan	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 22	Local Therapy Poster Session	LTP-4	10181	A Propensity Score-Matched Comparison of Particle Therapy and Transarterial Chemoembolization for Hepatocellular Carcinoma	Tomoharu	Yamanaka	Japan	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 22	Local Therapy Poster Session	LTP-5	10068	Exploring the Efficacy of Systemic Inflammatory Markers in Predicting Outcomes Post Transarterial Chemoembolization (c TACE & deb TACE)	Rajata Prabhakar	Pande	India	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area
Poster	Poster Group 22	Local Therapy Poster Session	LTP-6	10033	Objective Response, Survival, and Downstaging After Yttrium-90 Radioembolization in Intermediate and Advanced Hepatocellular Carcinoma	Chieh-Ling	Yen	Taiwan	April 3 (Day 2)	15:45	16:15	16:21	6	Poster Area
Poster	Poster Group 22	Local Therapy Poster Session	LTP-7	10186	Widespread Peritoneal Seeding after Popping Phenomenon during Microwave Ablation for Hepatocellular Carcinoma: A Case Report	Takumi	Yanai	Japan	April 3 (Day 2)	15:45	16:21	16:27	6	Poster Area
Poster	Poster Group 23	Systemic Therapy Poster Session 1	STP1-1	10014	Superiority of ICI-Based Regimens Over TKIs in Advanced HCC: A Systematic Review and Meta-Analysis	Chih-Ming	Lin	Taiwan	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 23	Systemic Therapy Poster Session 1	STP1-2	10088	Comparative Outcomes of Immunotherapy plus Transarterial Therapy versus Systemic Therapy Alone in Hepatocellular Carcinoma: A Systematic Review	Dewi	Prasetyaningtyas	Indonesia	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 23	Systemic Therapy Poster Session 1	STP1-3	10016	COVID-19 Pandemic's Impact on the Global Disease Burden of HBV-related Hepatocellular Carcinoma in the Elderly	Yuwei	Wang	China	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 23	Systemic Therapy Poster Session 1	STP1-4	10031	COVID-19 Pandemic did not Affect the Treatment Uptake of Immunotherapy as the Treatment for Advanced Hepatocellular Carcinoma (HCC)	Vicki wing-ki	Hui	Hong Kong	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 24	Systemic Therapy Poster Session 2	STP2-1	10062	Early Clinical Outcomes of Nivolumab plus Ipilimumab Combination Therapy for Advanced Hepatocellular Carcinoma	Taro	Watabe	Japan	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 24	Systemic Therapy Poster Session 2	STP2-2	10189	Initial Experience with Nivolumab plus Ipilimumab for Unresectable Hepatocellular Carcinoma, Including Predictions of Efficacy and Safety	Hironao	Okubo	Japan	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 24	Systemic Therapy Poster Session 2	STP2-3	10105	Effects and Side Effects for Unresectable Hepatocellular Carcinoma Treated by Atezolizumab plus Bevacizumab	Masatoshi	Akamatsu	Japan	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 24	Systemic Therapy Poster Session 2	STP2-4	10156	Efficacy and Safety of Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma with Child-Pugh Class B: A Single-Center Study	Mayuko	Kondo	Japan	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 24	Systemic Therapy Poster Session 2	STP2-5	10092	Efficacy of Immunotherapy for Hepatocellular Carcinoma in the Elderly	Kojiro	kobayashi	Japan	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area
Poster	Poster Group 24	Systemic Therapy Poster Session 2	STP2-6	10211	Bevacizumab only Treatment Outcomes After Invasive Treatment of HCC Classified by Hepatitis Virus Type, Gender, and Age Group	Amarsanaa	Jazag	Mongolia	April 3 (Day 2)	15:45	16:15	16:21	6	Poster Area
Poster	Poster Group 25	Systemic Therapy Poster Session 3	STP3-1	10166	A Pretreatment Serum Cytokine Score Predicts Response to First-line Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma	Kazuki	Nagai	Japan	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 25	Systemic Therapy Poster Session 3	STP3-2	10188	Predictive Factors for Response to Dual Immune Checkpoint Inhibitor Therapy in Advanced Hepatocellular Carcinoma	Yutaro	Hori	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 25	Systemic Therapy Poster Session 3	STP3-3	10061	Evaluation of Liver and Spleen Volume Changes during Systemic Therapy for Hepatocellular Carcinoma	Koji	Uchino	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 25	Systemic Therapy Poster Session 3	STP3-4	10112	Effects of Combination Therapy with Tremelimumab and Durvalumab on Skeletal Muscle Mass and Cardiac Function in Patients with Unresectable Hepatocellular Carcinoma	Hideki	Nagumo	Japan	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 25	Systemic Therapy Poster Session 3	STP3-5	10079	Intratumor Vascular Lake Formation in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Lenvatinib	Takuma	Kaneko	Japan	April 3 (Day 2)	15:00	15:24	15:30	6	Poster Area
Poster	Poster Group 26	Systemic Therapy Poster Session 4	STP4-1	10110	Outcomes of Locoregional Therapy followed by Combination Immunotherapy for Unresectable Hepatocellular Carcinoma	Takeshi	Okamoto	Japan	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 26	Systemic Therapy Poster Session 4	STP4-2	10152	Continuing or Switching Systemic Therapy Combined with Locoregional Therapy Defines a Personalized Strategy for Oligoprogression in Hepatocellular Carcinoma: A Multicenter Retrospective Study	Hongli	Yu	China	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 26	Systemic Therapy Poster Session 4	STP4-3	10044	Clinical Outcomes of TACE/TAI Using Cisplatin Combined with Lenvatinib as Second-line Therapy After Failure or Intolerance to Immune Checkpoint Inhibitors	Masaki	Yoshikawa	Japan	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 26	Systemic Therapy Poster Session 4	STP4-4	10093	Two Cases of Unresectable Hepatocellular Carcinoma Treated with LEN-TACE for Local Control during Dual Immune Checkpoint Inhibitor Therapy	Yusuke	Masuda	Japan	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 26	Systemic Therapy Poster Session 4	STP4-5	10198	The Evaluation of Clinical Impact of Additional TACE to Lenvatinib for HCC Patients	Jun	Arai	Japan	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area
Poster	Poster Group 26	Systemic Therapy Poster Session 4	STP4-6	10168	The Impact of Scheduled LEN-TACE on Tumor Microenvironment for BCLC-B HCC	Jun	Arai	Japan	April 3 (Day 2)	15:45	16:15	16:21	6	Poster Area
Poster	Poster Group 26	Systemic Therapy Poster Session 4	STP4-7	10099	Lenvatinib plus Drug-eluting Bead Transarterial Chemoembolization for Large Hepatocellular Carcinoma beyond the up to 7 Criteria	Mariko	Irizato	Japan	April 3 (Day 2)	15:45	16:21	16:27	6	Poster Area
Poster	Poster Group 27	Systemic Therapy Poster Session 5	STP5-1	10002	Toxicity Turned Tolerance: Hematologic Adverse Events Managed Successfully in Hepatocellular Carcinoma with VP4 Portal Vein Tumor Thrombus under Atezolizumab-bevacizumab: A Case Report from Vietnam	Phuong Thi	Dinh	Viet Nam	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 27	Systemic Therapy Poster Session 5	STP5-2	10170	Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma in Patients with Severe Renal Impairment	Takashi	Nishimura	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 27	Systemic Therapy Poster Session 5	STP5-3	10084	A Super-Elderly Male with Multiple Hepatocellular Carcinoma Achieving Long-Term Survival by Repeated Percutaneous Ablation Combined with Lenvatinib	Maki	Tobari	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 27	Systemic Therapy Poster Session 5	STP5-4	10129	Desired Outcome of the STRIDE Regimen in an Advanced HCC Patient with Multiple Poor Prognostic Factors Outside HIMALAYA Trial Criteria: A Case Report	Ngan	Nguyen	Viet Nam	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 27	Systemic Therapy Poster Session 5	STP5-5	10039	Successful Transcatheter Aortic Valve Implantation Enabling Continuation of Systemic Chemotherapy in a Patient with Hepatocellular Carcinoma and Severe Aortic Stenosis: A Case Report	Kaho	Miyazaki	Japan	April 3 (Day 2)	15:00	15:24	15:30	6	Poster Area
Poster	Poster Group 28	Systemic Therapy Poster Session 6	STP6-1	10050	Subconjunctival Hemorrhage and Corneal Graft Failure following Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma: A Case Report	Tomoharu	Yamada	Japan	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 28	Systemic Therapy Poster Session 6	STP6-2	10150	Progressive Multifocal Leukoencephalopathy During Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma: A Case Report	Tamami	Abe	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 28	Systemic Therapy Poster Session 6	STP6-3	10071	A Case of Hepatocellular Carcinoma with Rectal Fistula Induced by Lenvatinib in a Patient with Crohn's Disease	Shigeki	Yano	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 28	Systemic Therapy Poster Session 6	STP6-4	10164	Stepwise Immune Re-sensitization Induced by Short-Term VEGF Inhibition Enhances Antitumor Efficacy of Repeated Durvalumab									

Type	Group No.	Session Name	Presentation No.	Submission No.	Title	First Name	Family Name	Country/District	Day	Session Start	Start of each	End of each	Min.	Place
Poster	Poster Group 29	Systemic Therapy Poster Session 7	STP7-1	10000	Exceptional Long-term Survival with Low-dose FP Regimen Hepatic Arterial Infusion Chemotherapy after Immune and TKI Failure in Advanced Hepatocellular Carcinoma: A Case Report from Vietnam	Huy_Van	Nguyen	Viet Nam	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 29	Systemic Therapy Poster Session 7	STP7-2	10153	Evaluation of the Efficacy of Sequential Therapy with New FP and Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Cacinoma	Akihiro	Deguchi	Japan	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 29	Systemic Therapy Poster Session 7	STP7-3	10157	5-fluorouracil plus Cisplatin Versus Cisplatin in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Randomized Controlled Trial	Hidetoshi	Nakagawa	Japan	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 29	Systemic Therapy Poster Session 7	STP7-4	10043	Near-Complete Response to Nivolumab+Ipilimumab in HCC With IVC Invasion: An Exceptional Outcome Beyond Trial Eligibility	Naoki	Takamura	Japan	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 29	Systemic Therapy Poster Session 7	STP7-5	10194	Dramatic Complete Response to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma with Massive Liver Involvement	Yutaka	Yata	Japan	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area
Poster	Poster Group 29	Systemic Therapy Poster Session 7	STP7-6	10140	Selective Control of Pulmonary Metastases by Chemotherapy in Hepatitis C-related Hepatocellular Carcinoma: A Case Report	Yoshie	Kadota	Japan	April 3 (Day 2)	15:45	16:15	16:21	6	Poster Area
Poster	Poster Group 29	Systemic Therapy Poster Session 7	STP7-7	10028	Dual Tumor Response to Sequential Immune Checkpoint Inhibitors in Synchronous HCC and ESCC: A Case Report	Kotaro	Matsumoto	Japan	April 3 (Day 2)	15:45	16:21	16:27	6	Poster Area
Poster	Poster Group 30	Late Braeker Poster Session 1	LBP1-1	10245	Recurrence After Achieving a Drug-Free State Following Response to Systemic Therapy in Hepatocellular Carcinoma: A Retrospective Case Series	Takanobu	Kanaya	Japan	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 30	Late Braeker Poster Session 1	LBP1-2	10258	An Analysis of Progression Patterns After Response to Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma	Haruka	Anzai	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 30	Late Braeker Poster Session 1	LBP1-3	10270	Real-World Outcomes and Characteristics of Responders in Advanced Hepatocellular Carcinoma Treated with Durvalumab/Tremelimumab	Takuya	Yonemoto	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 30	Late Braeker Poster Session 1	LBP1-4	10238	Real-World Early Experience with Ipilimumab Plus Nivolumab (IPINIVO) for Advanced Hepatocellular Carcinoma	Wataru	Ueno	Japan	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 30	Late Braeker Poster Session 1	LBP1-5	10269	Lessons Learned from 1,716 Hepatobiliary Cancers: Real World Outcomes of Immune Checkpoint Inhibitor Therapy	Shinya	Takaoka	Japan	April 3 (Day 2)	15:00	15:24	15:30	6	Poster Area
Poster	Poster Group 31	Late Braeker Poster Session 2	LBP2-1	10234	Exploring the Value of Imaging Indicators in Predicting TACE Refractoriness in Hepatocellular Carcinoma Based on Contrast-Enhanced CT	Ying	Lei	China	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 31	Late Braeker Poster Session 2	LBP2-2	10233	Trans Arterial Chemoembolization Combined with Immunotherapy for BCLC Stage B Hepatocellular Carcinoma: A Systematic Review and Meta-analysis	Andree	Kurniawan	Indonesia	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 31	Late Braeker Poster Session 2	LBP2-3	10252	Safety and Recurrence Patterns of Ablation After Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma	Yasuyuki	Komiyama	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 31	Late Braeker Poster Session 2	LBP2-4	10243	Clinical Response of Brain Metastasis From Hepatocellular Carcinoma Treated with a Multimodal Approach Using Lenvatinib and Radiotherapy: A Case Report	Quang Vinh	Dang	Viet Nam	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 31	Late Braeker Poster Session 2	LBP2-5	10242	Hepatocellular Carcinoma with Submandibular and Sternal Manubrial Metastases: Tumor Growth Rate Based Dynamic Assessment and Regorafenib Combined with a Tonifying Eliminating Harmonizing Strategy	huijie	Li	China	April 3 (Day 2)	15:00	15:24	15:30	6	Poster Area
Poster	Poster Group 31	Late Braeker Poster Session 2	LBP2-6	10271	Triple Trouble: A Case of Hepatocellular Carcinoma in a Patient with Previous Renal and Colonic Malignancies	Cleo Christille Lynn G.	Lom-OC	Philippines	April 3 (Day 2)	15:00	15:30	15:36	6	Poster Area
Poster	Poster Group 32	Late Braeker Poster Session 3	LBP3-1	10251	A CT-Based Hybrid Model for Predicting CK19-Positive Hepatocellular Carcinoma and Assessing Prognosis: A Multicenter Study	Yawen	Wang	China	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 32	Late Braeker Poster Session 3	LBP3-2	10263	Development of a Novel Erythrocyte-Related Risk Score for Prognosis Prediction in Hepatocellular Carcinoma Patients	Huiwen	Yan	China	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 32	Late Braeker Poster Session 3	LBP3-3	10262	Anemia Predicts Poor Prognosis in HBV-Related Hepatocellular Carcinoma: a Large-Scale Retrospective Study	Huiwen	Yan	China	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 32	Late Braeker Poster Session 3	LBP3-4	10253	Assessment of Liver Fibrosis Severity in Patients Infected with Hepatitis B and C Viruses	Dolgormaa	Batsaikhan	Mongolia	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 32	Late Braeker Poster Session 3	LBP3-5	10227	Level of IL-6 is Directly Correlated with the Severity of Hepatitis B	Mohamed Shafi	Mahboob Ali	Malaysia	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area
Poster	Poster Group 33	Late Braeker Poster Session 4	LBP4-1	10244	The Mongolian and the Southeast Asian Cluster: Mapping the 2022 Liver Cancer Epidemic Across Asia	Ulil_Albab	Habibah	Indonesia	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 33	Late Braeker Poster Session 4	LBP4-2	10264	Temporal Trends in Hepatocellular Carcinoma Mortality in a Historically High-Risk Region of Japan: A Population-Based Study from Yamanashi Prefecture	Hiroyuki	Amano	Japan	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 33	Late Braeker Poster Session 4	LBP4-3	10256	Long-term Trends in Incidence, Stage, and Survival of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Prospective Cancer Registry Analysis from 2006 to 2024	Shuntaro	Obi	Japan	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 33	Late Braeker Poster Session 4	LBP4-4	10266	Increasing Proportion but Stable Incidence of Non-B Non-C Hepatocellular Carcinoma in the Post-DAA Era: A Real-World Cohort Study	Hiroyuki	Amano	Japan	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 33	Late Braeker Poster Session 4	LBP4-5	10265	Efforts to Combat Hepatitis C in a Leading High-Prevalence Prefecture in Eastern Japan	Hiroyuki	Amano	Japan	April 3 (Day 2)	15:00	15:24	15:30	6	Poster Area
Poster	Poster Group 33	Late Braeker Poster Session 4	LBP4-6	10229	Advancing Toward WHO's HCV Zero Goals: Performance Evaluation of the Elecsys HCV Duo for Simultaneous Antibody and Core Antigen Detection	Yosuke	Hirotsu	Japan	April 3 (Day 2)	15:00	15:30	15:36	6	Poster Area
Poster	Poster Group 33	Late Braeker Poster Session 4	LBP4-7	10249	Identification of Patients with Positive Hepatitis Virus Markers by Hepatitis Medical Care Coordinators	Keiji	Kaneko	Japan	April 3 (Day 2)	15:00	15:36	15:42	6	Poster Area
Poster	Poster Group 34	Late Braeker Poster Session 5	LBP5-1	10257	Single-Cell Profiling Reveals Novel Insights into Vessel Co-Option in Human Colorectal Liver Metastases	Lolita	Dokshokova	Denmark	April 3 (Day 2)	15:00	15:00	15:06	6	Poster Area
Poster	Poster Group 34	Late Braeker Poster Session 5	LBP5-2	10259	Unbiased Single-Cell Transcriptome-Proteome Co-Profiling Reveals Post-Transcriptional Buffering in Rare CSF-CTCs	Liyong	He	China	April 3 (Day 2)	15:00	15:06	15:12	6	Poster Area
Poster	Poster Group 34	Late Braeker Poster Session 5	LBP5-3	10268	Research on Targeted TGF-beta Pathway Inhibitors in Hepatocellular Carcinoma	Liang	Shi	China	April 3 (Day 2)	15:00	15:12	15:18	6	Poster Area
Poster	Poster Group 34	Late Braeker Poster Session 5	LBP5-4	10267	Research on Targeted FGFR4 Inhibitors in Hepatocellular Carcinoma	Yuting	Chen	China	April 3 (Day 2)	15:00	15:18	15:24	6	Poster Area
Poster	Poster Group 35	Late Braeker Poster Session 6	LBP6-1	10237	Development of a Novel Flavonoid Derivative with a Potent Anti-steatosis Activity in HepG2 Cells for Therapeutic Use in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)	Jaslan	Densumite	Thailand	April 3 (Day 2)	15:45	15:45	15:51	6	Poster Area
Poster	Poster Group 35	Late Braeker Poster Session 6	LBP6-2	10247	A Systematic Evaluation of Network Pharmacology Approaches for Elucidating Mechanisms and Therapeutic Effects of Herbal Medicines	Won-Yung	Lee	Korea	April 3 (Day 2)	15:45	15:51	15:57	6	Poster Area
Poster	Poster Group 35	Late Braeker Poster Session 6	LBP6-3	10255	The Mechanism of Compound Kushen Injection in Regulating Phosphatidylcholine-Mediated NK Cell Suppression of Liver Cancer Ascites	Hao	Liu	China	April 3 (Day 2)	15:45	15:57	16:03	6	Poster Area
Poster	Poster Group 35	Late Braeker Poster Session 6	LBP6-4	10261	Efficacy of Yangyin Fuzheng Jiedu Prescription for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: An Evaluation Using Five Propensity Score Methods	Wanxin	Shi	China	April 3 (Day 2)	15:45	16:03	16:09	6	Poster Area
Poster	Poster Group 35	Late Braeker Poster Session 6	LBP6-5	10260	Yangyin Fuzheng Jiedu Prescription Improves Survival in HBV Related Hepatocellular Carcinoma Patients with Anemia: A Promising Herbal Formula Under Translation	Wanxin	Shi	China	April 3 (Day 2)	15:45	16:09	16:15	6	Poster Area